Health Care Down on Earnings Doubts -- Health Care Roundup

Dow Jones04-07

Health-care companies fell as doubts about the earnings outlook for the sector offset deal activity.

Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes life-threatening hunger. It was the latest in a series of deals in the rare-disease area.

Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza.

Obesity drug makers Novo Nordisk and Eli Lilly fell as competition in the weight-loss category continued to intensify.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

April 06, 2026 17:15 ET (21:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625604743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625604743","market":"fut","top_or_hot":-1,"title":"Health Care Down on Earnings Doubts -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as doubts about the earnings outlook for the sector offset deal activity. \n</p>\n<p>\n  Neurocrine Biosciences agreed to buy <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes life-threatening hunger. It was the latest in a series of deals in the rare-disease area. \n</p>\n<p>\n  Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. \n</p>\n<p>\n  Obesity drug makers <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Eli Lilly fell as competition in the weight-loss category continued to intensify. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 17:15 ET (21:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down on Earnings Doubts -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down on Earnings Doubts -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-07 05:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as doubts about the earnings outlook for the sector offset deal activity. \n</p>\n<p>\n  Neurocrine Biosciences agreed to buy <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes life-threatening hunger. It was the latest in a series of deals in the rare-disease area. \n</p>\n<p>\n  Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. \n</p>\n<p>\n  Obesity drug makers <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Eli Lilly fell as competition in the weight-loss category continued to intensify. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 17:15 ET (21:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2625604743","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625604743","pubTimestamp":1775510100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies fell as doubts about the earnings outlook for the sector offset deal activity.Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes life-threatening hunger. It was the latest in a series of deals in the rare-disease area.Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza.Obesity drug makers Novo Nordisk and Eli Lilly fell as competition in the weight-loss category continued to intensify.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR"},"translate_title":"医疗保健因盈利疑虑而下跌——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5},"content_text":"Health-care companies fell as doubts about the earnings outlook for the sector offset deal activity. \n\n\n  Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes life-threatening hunger. It was the latest in a series of deals in the rare-disease area. \n\n\n  Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. \n\n\n  Obesity drug makers Novo Nordisk and Eli Lilly fell as competition in the weight-loss category continued to intensify. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 17:15 ET (21:15 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625604743","isCrawlerRequest":true}